Key result
The wearable Novacor left ventricular assist system controller achieved a 66% survival to transplant rate, similar to the 60% survival rate observed with the console controller.
Why the study?
Does a wearable controller for the Novacor LVAS maintain survival to transplant compared to a console controller in patients with end-stage heart disease?
Population
211 patients with end-stage heart disease requiring a bridge to cardiac transplantation.
Comparison
Wearable controller for the Novacor Left… vs Console-based extracorporeal controller for the…
Design
Cohort
Follow-up
Mean duration of use 51 days and 42 days
Authors
Loading...
May enable mobility in LVAS patients without survival loss; leaves open randomized confirmation of equivalence.
Cohort (n=211)
Does a wearable controller for the Novacor LVAS maintain survival to transplant compared to a console controller in patients with end-stage heart disease?
Absolute Event Rate: 66% vs 60%
A wearable controller for the Novacor LVAS provides comparable survival to transplant as the traditional console system while enabling patient mobility.
Miller et al. (1994) conducted a cohort in End-stage heart disease (n=211). Wearable control system for the Novacor left ventricular assist system (LVAS) vs. Console based extracorporeal controller was evaluated on Survival to transplant. The wearable Novacor left ventricular assist system controller achieved a 66% survival to transplant rate, similar to the 60% survival rate observed with the console controller.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: